Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. Secondary objectives included comparing rosuvasta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2003-07, Vol.92 (2), p.152-160
Hauptverfasser:	Jones, Peter H, Davidson, Michael H, Stein, Evan A, Bays, Harold E, McKenney, James M, Miller, Elinor, Cain, Valerie A, Blasetto, James W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Atorvastatin Biological and medical sciences Cholesterol, LDL - blood Cholesterol, LDL - drug effects Comparative analysis Dose-Response Relationship, Drug Drug therapy Female Fluorobenzenes - administration & dosage Fluorobenzenes - adverse effects Fluorobenzenes - therapeutic use General and cellular metabolism. Vitamins Heptanoic Acids - administration & dosage Heptanoic Acids - adverse effects Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Pravastatin - administration & dosage Pravastatin - adverse effects Pravastatin - therapeutic use Pyrimidines Pyrroles - administration & dosage Pyrroles - adverse effects Pyrroles - therapeutic use Rosuvastatin Calcium Safety Simvastatin - administration & dosage Simvastatin - adverse effects Simvastatin - therapeutic use Sulfonamides Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!